The FRAX score in postmenopausal women with subclinical hyperthyroidism

2014 ◽  
Author(s):  
Snezana Polovina ◽  
Vera Popovic-Brkic ◽  
Dragan Micic ◽  
Natasa Milic ◽  
Mirjana Sumarac-Dumanovic ◽  
...  
Keyword(s):  
Postmenopausal Women ◽  
Subclinical Hyperthyroidism ◽  
Frax Score

Decreased serum IGF-I and dehydroepiandrosterone sulphate may be risk factors for the development of reduced bone mass in postmenopausal women with endogenous subclinical hyperthyroidism

1997 ◽  
Vol 136 (3) ◽  
pp. 277-281 ◽  
Author(s):  
János Földes ◽  
Péter Lakatos ◽  
Júlia Zsadányi ◽  
Csaba Horváth
Keyword(s):  
Risk Factors ◽  
Femoral Neck ◽  
Postmenopausal Women ◽  
Premenopausal Women ◽  
Subclinical Hyperthyroidism ◽  
Dehydroepiandrosterone Sulphate ◽  
Additional Risk ◽  
Igf I ◽  
Overt Hyperthyroidism ◽  
Igfbp 3

Abstract Postmenopausal women with endogenous subclinical hyperthyroidism seem to have reduced bone mass, which does not correlate with serum thyroid hormone levels. Relative insufficiencies of IGF-I and dehydroepiandrosterone sulphate (DHEAS) might be additional risk factors for low bone density in these patients. We measured IGF-I, IGF-binding protein-3 (IGFBP-3) and DHEAS levels together with bone mineral density (BMD) of the femoral neck and lumbar spine in women with an autonomously functioning thyroid nodule. Sixty-three women were classified as subclinical hyperthyroid (31 pre- and 32 postmenopausal) and 39 as overt hyperthyroid (16 pre- and 23 postmenopausal) and results were compared with data obtained from 41 age-matched euthyroid healthy women. In premenopausal women BMD was reduced only in the overt hyperthyroid group, and only in the spine, to 92% (P < 0·05). Serum IGF-I as well as IGFBP-3 were increased in the manifest hyperthyroid group, to 157% (P < 0·001) and 129% (P < 0·05) respectively, whereas DHEAS levels did not change in either premenopausal patient group. In postmenopausal women BMD was significantly reduced both in the subclinical hyperthyroid group (spine to 90% and femoral neck to 88%; P < 0·05), as well as in the hyperthyroid group (spine to 78% and femoral neck to 86%; P < 0·01). In contrast to premenopausal women, serum IGF-I and IGFBP-3 did not change in the two groups who were postmenopausal and serum DHEAS levels were reduced to 58% (P < 0·001) in both postmenopausal groups with subclinical as well as overt hyperthyroidism. In the same two groups of patients, serum IGF-I and DHEAS levels correlated with BMD (femoral neck; both r = 0·50, P < 0·05). In conclusion, women with a solitary autonomous thyroid nodule with subclinical hyperthyroidism have reduced BMD only if they are postmenopausal. This is probably due to the effect of subtle increases in thyroid hormone production together with lack of oestrogen protection of the skeleton. But additional risk factors for the development of enhanced bone loss might be a state of relative IGF-I and DHEAS insufficiency in these patients as well as in postmenopausal women with overt hyperthyroidism. European Journal of Endocrinology 136 277–281

scholarly journals OPYT PRIMENENIYa PROFILAKTIChESKOY DOZY ALENDRONATA (FOSAMAKS 35 mg) DLYa LEChENIYa OSTEOPOROZA u zhenshchin v postmenopauzes subklinicheskim tireotoksikozom

2007 ◽  
Vol 10 (1) ◽  
pp. 12-19
Author(s):  
Zh E BELAYa ◽  
L Ya ROZhINSKAYa ◽  
G S KOLESNIKOVA ◽  
A V IL'IN ◽  
N I SAZONOVA ◽  
...  
Keyword(s):  
Bone Metabolism ◽  
Postmenopausal Women ◽  
Type I Collagen ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Type I ◽  
Subclinical Hyperthyroidism ◽  
High Cholesterol ◽  
Baseline Visit ◽  
High Cholesterol Level

The aim was to estimate the effects of treatment with alendronate (Fosomax 35 mg) in postmenopausal women with osteoporosis and subclinical hyperthyroidism. Thirty postmenopausal women (64 (60-69) years old) with osteoporosis (T-score ≤ -2,5) and subclinical hyperthyroidism (77% with endogenous subclinical hyperthyroidism and 23% on L-thyroxine suppres-sive therapy after thyroidectomy due to differentiated thyroid cancer) were randomly assigned into two groups: 1-14 women received Fosamax 35 mg a week in combination with 500 mg of calcium and 400 UI of Vitamin D3 (VD) daily; 2-16 women received 1000 mg of calcium and 800 UI of VD daily. Euthyroidism was achieved in all women with endogenous subclinical hyperthyroidism. An increase in physical activity was recommended to all patients and a hypolipidemic diet was given to those who had had high cholesterol level. Biochemical parameters (calcium (Ca), phosphorous (P), creatinine (Cre), alkaline phosphatase (ALP), cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL), triglycerides (TG), cholesterol/HDL ratio) in fasting serum as well as calcium/creatinine ratio in fasting urine (U-Ca/U-Cre); biochemical markers of bone metabolism: osteocalcin (OC) and C-terminal telopeptide of type I collagen (b-CTx) serum ("ECLIA", Roche Elecsys 1010/2010), BMD (DXA; Prodigy, Lunar) at the lumbar spine (L1-L4), femoral neck (FN), total hip (TH) and radius total (RT) were measured at the baseline visit and after 1 year of treatment. At the baseline visit there were not found any differences between the 1 and the 2 groups. After 12 months of treatment the markers of bone metabolism as well as ALP decreased significantly in both groups, though the decreases were significantly greater (p

scholarly journals Performance of FRAX in Predicting Fractures in US Postmenopausal Women with Varied Race and Genetic Profiles

2020 ◽  
Vol 9 (1) ◽  
pp. 285 ◽  
Author(s):  
Qing Wu ◽  
Xiangxue Xiao ◽  
Yingke Xu
Keyword(s):  
African American ◽  
African American Women ◽  
Postmenopausal Women ◽  
Assessment Tool ◽  
Genetic Risk Score ◽  
Fracture Probability ◽  
Genetic Profile ◽  
Mineral Density ◽  
Frax Score ◽  
Whi Study

Background: Whether the Fracture Risk Assessment Tool (FRAX) performed differently in estimating the 10-year fracture probability in women of different genetic profiling and race remained unclear. Methods: The genomic data in the Women’s Health Initiative (WHI) study was analyzed (n = 23,981). The genetic risk score (GRS) was calculated from 14 fracture-associated single nucleotide polymorphisms (SNPs) for each participant. FRAX without bone mineral density (BMD) was used to estimate fracture probability. Results: FRAX significantly overestimated the risk of major osteoporotic fracture (MOF) in the WHI study. The most significant overestimation was observed in women with low GRS (predicted/observed ratio (POR): 1.61, 95% CI: 1.45–1.79) specifically Asian women (POR: 3.5, 95% CI 2.48–4.81) and in African American women (POR: 2.59, 95% CI: 2.33–2.87). Compared to the low GRS group, the 10-year probability of MOF adjusted for the FRAX score was 21% and 30% higher in the median GRS group and high GRS group, respectively. Asian, African American, and Hispanic women respectively had a 78%, 76%, and 56% lower hazard than Caucasian women after the FRAX score was adjusted. The results were similar for hip fractures. Conclusions: Our study suggested the FRAX performance varies significantly by both genetic profile and race in postmenopausal women.

Reduced bone mass detected by bone quantitative ultrasonometry and DEXA in pre- and postmenopausal women with endogenous subclinical hyperthyroidism

Maturitas ◽  
2004 ◽  
Vol 48 (3) ◽  
pp. 299-306 ◽  
Author(s):  
Libuse Tauchmanovà ◽  
Vincenzo Nuzzo ◽  
Antonio Del Puente ◽  
Francesco Fonderico ◽  
Antonella Esposito-Del Puente ◽  
...  
Keyword(s):  
Bone Mass ◽  
Postmenopausal Women ◽  
Subclinical Hyperthyroidism ◽  
Quantitative Ultrasonometry

Frax score calculations in postmenopausal women with subclinical hypothyroidism

HORMONES ◽  
2013 ◽  
Vol 12 (3) ◽  
pp. 439-448 ◽  
Author(s):  
Snezana Polovina ◽  
Vera Popovic ◽  
Leonidas Duntas ◽  
Natasa Milic ◽  
Dragan Micic
Keyword(s):  
Postmenopausal Women ◽  
Subclinical Hypothyroidism ◽  
Frax Score

scholarly journals Thyroid Hormone Diseases and Osteoporosis

2020 ◽  
Vol 9 (4) ◽  
pp. 1034 ◽  
Author(s):  
Alessandro P. Delitala ◽  
Angelo Scuteri ◽  
Carlo Doria
Keyword(s):  
Bone Turnover ◽  
Thyroid Hormones ◽  
Bone Metabolism ◽  
Postmenopausal Women ◽  
Overt Hypothyroidism ◽  
Subclinical Hyperthyroidism ◽  
Mineral Density ◽  
Risk Of Fracture ◽  
Increased Risk ◽  
Bone Structures

Thyroid hormones are essential for normal skeletal development and normal bone metabolism in adults but can have detrimental effects on bone structures in states of thyroid dysfunction. Untreated severe hyperthyroidism influences the degree of bone mass and increases the probability of high bone turnover osteoporosis. Subclinical hyperthyroidism, defined as low thyrotropin (TSH) and free hormones within the reference range, is a subtler disease, often asymptomatic, and the diagnosis is incidentally made during screening exams. However, more recent data suggest that this clinical condition may affect bone metabolism resulting in decreased bone mineral density (BMD) and increased risk of fracture, particularly in postmenopausal women. The main causes of exogenous subclinical hyperthyroidism are inappropriate replacement dose of thyroxin and TSH suppressive L-thyroxine doses in the therapy of benign thyroid nodules and thyroid carcinoma. Available data similarly suggest that a long-term TSH suppressive dose of thyroxin may decrease BMD and may induce an increased risk of fracture. These effects are particularly observed in postmenopausal women but are less evident in premenopausal women. Overt hypothyroidism is known to lower bone turnover by reducing both osteoclastic bone resorption and osteoblastic activity. These changes in bone metabolism would result in an increase in bone mineralization. At the moment, there are no clear data that demonstrate any relationship between BMD in adults and hypothyroidism. Despite these clinical evidences, the cellular and molecular actions of thyroid hormones on bone structures are not complete clear.

scholarly journals Performance of FRAX in predicting fracture in the US postmenopausal women with varied race and genetic profiles

2020 ◽  
Author(s):  
Qing Wu ◽  
Xiangxue Xiao ◽  
Yingke Xu
Keyword(s):  
African American ◽  
African American Women ◽  
Postmenopausal Women ◽  
Assessment Tool ◽  
Genetic Risk Score ◽  
Fracture Probability ◽  
Nucleotide Polymorphisms ◽  
Mineral Density ◽  
Genetic Profiling ◽  
Frax Score

AbstractBackgroundWhether the Fracture Risk Assessment Tool (FRAX) performed differently in estimating the 10-year fracture probability in women of different genetic profiling and race remained unclear.MethodsThe genomic data in the Women’s Health Initiative study was analyzed (n=23,981). the genetic risk score (GRS) was calculated from 14 fracture-associated single nucleotide polymorphisms (SNPs) for each participant. FRAX without bone mineral density (BMD) was used to estimate fracture probability.ResultsFRAX significantly overestimated the risk of major osteoporotic fracture (MOF) in the WHI study. The most enormous overestimation was observed in women with low GRS (predicted/observed ratio [POR]: 1.61, 95% CI: 1.45-1.79), in Asian women (POR: 3.5, 95% CI 2.48-4.81), and in African American women (POR: 2.59, 95% CI: 2.33-2.87). Compared to the low GRS group, the 10-year probability of MOF adjusted for the FRAX score was 21% and 30% higher in median GRS group and high GRS group, respectively. Asian, African American, and Hispanic women respectively had a 78%, 76%, and 56% lower hazard than Caucasian women after the FRAX score was adjusted for. The results were similar when for hip fractures.ConclusionsOur study suggested the FRAX performance varies significantly by both genetic profiling and race in postmenopausal women.

Sign in / Sign up

Export Citation Format

Share Document